# Triptorelin

> Triptorelin is a synthetic GnRH agonist decapeptide formulated as a long-acting intramuscular depot. Like other GnRH agonists, it produces an initial gonadotropin surge followed by sustained pituitary desensitization, lowering testosterone or estrogen to castrate/menopausal levels within weeks. It is approved for advanced prostate cancer and used off-label or under separate approvals for endometriosis, central precocious puberty, and pituitary downregulation in assisted reproduction. Treatment duration and depot strength are determined by the prescribing physician based on the underlying condition.

- URL: https://www.lifeconverted.com/peptides/triptorelin
- Also known as: Decapeptyl, Trelstar, Diphereline
- Primary category: Other & Clinical
- Effectiveness rank: #4 in Other & Clinical
- Evidence level: Well studied
- Route: Intramuscular (Administered as an intramuscular depot injection at monthly, 3-monthly, or 6-monthly intervals depending on the formulation used.)
- Dose range: 3.75-22.5 mg
- Dose tiers: low 3.75 mg; moderate 11.25 mg; high 22.5 mg
- Half-life: Parent peptide half-life approximately 3 hours; depot formulation extends the effective suppressive duration to months
- Timing: As directed by your clinician
- Cycle: Continuous per oncology or gynecologic protocol, often months to years on, Discontinued only per prescriber decision off (Not a self-cycled research peptide; duration and depot strength are set by the treating physician.)
- Storage: Refrigerate at 2-8°C prior to reconstitution; some depot kits are stable at room temperature short-term per the manufacturer's insert.

## Mechanism of action

Continuous GnRH receptor agonism initially stimulates, then progressively desensitizes and downregulates, pituitary gonadotrope GnRH receptors. This shifts the axis from an initial LH/FSH surge (and transient rise in sex steroids) to sustained suppression of gonadotropin release and downstream sex-hormone production after roughly two to four weeks of therapy.

## Reported benefits

- Androgen deprivation for advanced prostate cancer
- Suppresses estrogen-driven pain in endometriosis
- Delays progression of central precocious puberty
- Enables pituitary downregulation in controlled ovarian stimulation (IVF) protocols

## Reported side effects

- Initial disease/tumor symptom flare
- Hot flashes
- Decreased libido
- Reduced bone mineral density with prolonged use
- Injection site reactions

## Common protocols

- Advanced prostate cancer androgen deprivation therapy
- Endometriosis symptom suppression
- Central precocious puberty management
- Pituitary downregulation in IVF stimulation cycles

---

Educational information only, not medical advice. Full disclaimer: https://www.lifeconverted.com/disclaimer